Does Emtricitabine Rilpivirine And Tenofovir Disoproxil Fumarate Interact with Cyp3a Inducers?
Emtricitabine Rilpivirine And Tenofovir Disoproxil Fumarate and Cyp3a Inducers have a major drug interaction according to U.S. FDA drug labeling data. Coadministration may result in decreased plasma concentrations of rilpivirine and loss of virologic response and possible resistance to rilpivirine or to the class of NNRTIs. The mechanism involves rilpivirine is primarily metabolized by cyp3a; induction increases clearance. Patients taking both medications should consult their healthcare provider before starting, stopping, or changing the dosage of either drug. This information is based on official FDA drug labeling sourced from OpenFDA and the NIH National Library of Medicine.
- Severity
- Major
- Emtricitabine Rilpivirine And Tenofovir Disoproxil Fumarate Class
- Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor
- Management
- Close medical supervision required
- Data Source
- U.S. FDA via OpenFDA
How This Interaction Works
The interaction between Emtricitabine Rilpivirine And Tenofovir Disoproxil Fumarate and Cyp3a Inducers occurs because rilpivirine is primarily metabolized by cyp3a; induction increases clearance. Clinically, this means coadministration may result in decreased plasma concentrations of rilpivirine and loss of virologic response and possible resistance to rilpivirine or to the class of nnrtis. This is classified as a major interaction, meaning it could cause serious harm if not properly managed. Your healthcare provider may need to adjust dosages, substitute one medication, or increase monitoring frequency.
What To Tell Your Doctor or Pharmacist
If you are taking Emtricitabine Rilpivirine And Tenofovir Disoproxil Fumarate and your doctor is considering prescribing Cyp3a Inducers (or vice versa), make sure to:
- Inform your doctor and pharmacist of all current medications, including over-the-counter drugs and supplements
- Ask whether the benefits of combining these medications outweigh the risks for your specific situation
- Ask what symptoms to watch for that would indicate the interaction is causing problems
- Ask how frequently you should be monitored while these are co-prescribed
- Ask whether any dosage adjustments are needed
- Never stop or change either medication without first consulting your healthcare provider